Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
about
The involvement of TRPV1 in emesis and anti-emesisFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingThe effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study.Anti-emetics in development.Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew.Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutAprepitant and fosaprepitant: a 10-year review of efficacy and safetyAprepitant--a novel NK1-receptor antagonist.Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone.Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.Emerging drugs for chemotherapy-induced emesis.Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Treatment of Nausea and Vomiting During Chemotherapy.Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonistsDevelopment of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Pharmacologic management of postoperative nausea and vomiting.Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.Current advances in treatment of gastroparesis.Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew).Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion.Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.Successful management of refractory diabetic gastroparesis with long-term Aprepitant treatment.Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs.Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
P2860
Q26745801-DA82C353-B904-487C-B29B-2A733E0FF6A2Q28258863-EF41451D-DF1B-4301-ABA7-D7B9593FD114Q33891321-E483DCFE-DE55-4BBB-977C-B842F1E5BDC8Q34660860-C84E7108-0794-4304-849C-594961D7EDAFQ34987555-6648A8C4-37C1-4272-A820-6DD8D2F2003CQ35042464-A7E6353F-0428-4D0F-BFE1-89D797E48B44Q35236769-028B5632-4940-455E-8947-B88C4E855BE2Q35345557-438AB97F-0939-4A1E-942F-0C6385952A21Q35594000-5B3AEC1E-0B42-48BF-A924-C370B8444D5AQ35918427-445EDB83-E274-4A6B-80DD-493572BD3700Q36284018-52BCD5A6-DE48-4579-8E8B-712A212B317EQ36285281-EECC8EF2-C726-4C06-8A90-E49273EC70BBQ36400372-CE531E45-91F6-42BC-8976-4B6BAA3CF34FQ36407422-9C00B3C3-158F-4259-944F-3649889EC406Q36793614-E0608335-79EF-4E9F-A58A-2C08F9C041D6Q37316977-F12E0033-53CE-46FE-B5A0-39391A1B1361Q37503489-5403EFE0-28EA-4A56-BB7F-1193625EEBFCQ37677897-0963A194-036C-46BC-9CD9-81D9477845FDQ37761329-96780FD6-A7A3-4019-AB59-12AF6E576E6AQ37857329-6A23B094-CA83-4209-80D4-E9B74D74B09FQ37901057-FC245A96-B638-49BC-B99D-5B8760D7AA26Q38531668-F8894D57-5C78-4385-9A59-C79C1A3E3FD1Q38550545-F0B5B68C-53E5-4C2B-986A-56F6A4C6833CQ40978787-BA444F35-185A-4560-89E1-5ADDB8258B6DQ41438817-D0DE7C00-FC35-417A-BADF-8363DF4397D8Q42673458-2273C270-0D9A-4BBF-A897-DCAA31AF3165Q42735567-1B3DA229-5DEC-474F-B53C-99426700A7D2Q43019633-2D5026F9-4992-4FC3-B8B3-1F9C24E43C6EQ43032859-137491E1-19E6-437F-823B-BA531AD696C0Q43682443-4876C39D-35DD-479D-8468-AA71DFDB6C48Q44925317-A934420F-15AB-4C33-A4B9-646C7C68678CQ46044510-C0BADA67-535C-4995-8172-4DCC961A6624Q47944822-D1892CCC-0151-40CE-A7D2-C336C9547030Q48116794-1EA8A9AE-626C-438A-9FA0-2DA0BCF84594Q48243163-376AE7EA-266A-4EAF-BB09-A2EC055E6F9FQ48547468-6B4B5490-F211-4B1B-BB1D-06B5E572FAC9Q58828834-B065578A-8D5F-4E93-B3B5-D36EED2AC0D4
P2860
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Tachykinin NK1 receptor antago ...... ic agent cisplatin in ferrets.
@en
type
label
Tachykinin NK1 receptor antago ...... ic agent cisplatin in ferrets.
@en
prefLabel
Tachykinin NK1 receptor antago ...... ic agent cisplatin in ferrets.
@en
P2093
P1433
P1476
Tachykinin NK1 receptor antago ...... ic agent cisplatin in ferrets.
@en
P2093
Cascieri M
Hargreaves RJ
Ladduwahetty T
MacIntyre DE
MacLeod AM
P304
P356
10.1016/S0028-3908(96)00020-2
P577
1996-01-01T00:00:00Z